INTERVIEW: Bausch & Lomb eyes market listing as acquisition offers roll in
This article was originally published in Scrip
Executive Summary
The 160-year-old eye drug, surgery and consumer product specialist Bausch & Lomb checked a box on the to-do list for its return to the public markets with a stop at the 31st Annual JP Morgan Healthcare Conference in San Francisco, during a period when the company also is getting offers from Big Pharma suitors.
You may also be interested in...
Allergan’s Ophthalmology Focus Grows Beyond Restasis And Glaucoma
Allergan is building a diverse ophthalmology portfolio with a pipeline of drugs, devices and procedures that could bolster the company’s eye care revenue beyond Restasis and glaucoma medicines.
Ionis Invests For The Future In New Technologies, Manufacturing Innovation
Through partnerships with Bicycle and Metagenomi, Ionis is working on new chemistries and novel medicines. It is also expanding manufacturing capacity to enable its scientific growth.
Ionis Finds Its Footing Ahead Of Its First Big Commercial Step
Ionis will launch its first commercial product through a co-commercialization agreement with AstraZeneca early next year, in preparation for its first wholly-owned drug launches soon to follow.